Method of treatment

Abstract

The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.

1 . The use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.  
     
     
         2 . The use as claimed in  claim 1 , wherein the darifenacin is in the form of a pharmaceutically acceptable acid addition salt.  
     
     
         3 . The use as claimed in  claim 1 , wherein the darifenacin is in the form of its hydrobromide salt.  
     
     
         4 . The use as claimed in any one of the preceding claims, wherein the patients to be treated are suffering from wet overactive bladder.  
     
     
         5 . The method in any one of  claims 1  to  3 , wherein the patients to be treated are suffering from dry overactive bladder.  
     
     
         6 . The use as claimed in any one of the preceding claims, wherein the darifenacin, or a pharmaceutically acceptable derivative thereof, is administered in a dosage form that is adapted to release at least 10% of said darifenacin, or a pharmaceutically acceptable derivative thereof, in the lower gastrointestinal tract of the patients.  
     
     
         7 . The use as claimed in  claim 6 , wherein the dosage form is a slow release matrix tablet.  
     
     
         8 . Darifenacin, or a pharmaceutically acceptable derivative thereof, for use in the reduction of urgency in patients suffering from overactive bladder.  
     
     
         9 . A method of reducing urgency in patients suffering from overactive bladder, which comprises administering darifenacin, or a pharmaceutically acceptable derivative thereof, to a patient in need of such treatment.